D
DiogenX
Biotech & Life Sciences · Marseille, France · Founded 2019
Beta-Cell recovery to counter diabetes MoreLess
Developer of therapeutic services intended to serve diabetic patients. The company provides pancreatic beta-cell modulators for the treatment of type 1 and type 2 diabetes by developing a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, enabling patients to get benefits in terms of quality of life and survival. Keywords: Pharmaceuticals and Biotechnology, Autoimmune Disorder, Beta-Cell Recovery, Cell System, Diabetic Patient, Pancreatic Beta-Cells, Peripheral Target.
Talent graph
DiogenX's talent
Source: Dealroom Talent Intelligence.
Investors
8 investors on DiogenX's cap table
Sourced from Dealroom's funding history.
Global footprint
Where DiogenX has talent and traffic
team presence
Market sentiment
What the market is saying about DiogenX
An AI-synthesized read of the highest-engagement posts about DiogenX on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DiogenX on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.